Targeting of Costimulatory Molecules as a Therapeutic Approach in Inflammatory Bowel Disease

ISSN： 1173-8804

Source： BioDrugs, Vol.17, Iss.6, 2003-01, pp. : 395-411

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Probiotics and Inflammatory Bowel Disease

By Kwon J.H. Farrell R.J.

BioDrugs, Vol. 17, Iss. 3, 2003-01 ,pp. : 179-186

Adis International

Access to resources Recommend Favorite

Tolerability of Aminosalicylates in Inflammatory Bowel Disease

By Ishaq S.

BioDrugs, Vol. 15, Iss. 5, 2001-05 ,pp. : 339-349

Adis International

Access to resources Recommend Favorite

Sphingomyelinase Inhibition Suggests a Possible New Strategy for the Treatment of Inflammatory Bowel Disease

Current Drug Therapy, Vol. 3, Iss. 3, 2008-09 ,pp. : 218-225

Bentham Science Publishers

Access to resources Recommend Favorite

State of the Art: Therapeutical Strategies for the Treatment of Inflammatory Bowel Disease

Current Drug Therapy, Vol. 8, Iss. 2, 2013-06 ,pp. : 99-120

Bentham Science Publishers

Access to resources Recommend Favorite

The Role of Anti-Tumor Necrosis Factor-α Therapy in Pyoderma Gangrenosum Associated with Inflammatory Bowel Disease

By Reguiaï Ziad Grange Florent

American Journal of Clinical Dermatology, Vol. 8, Iss. 2, 2007-01 ,pp. : 67-77

Adis International

Access to resources Recommend Favorite